Libertyville, IL, United States of America

Earle E Bain

This inventor holds 1 USPTO granted patent. Top assignee: Abbott Laboratories Corporation. Active years: 2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Earle E Bain. Retrieved from https://idiyas.com/inventor/earle-e-bain

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Earle E Bain: Innovator in ADHD Treatment

Introduction

Earle E Bain is a notable inventor based in Libertyville, IL (US). He has made significant contributions to the field of pharmacology, particularly in the treatment of attention-deficit/hyperactivity disorder (ADHD). His innovative work has led to the development of compounds that target nicotinic receptors, providing new avenues for managing ADHD symptoms.

Latest Patents

Earle E Bain holds 1 patent for his invention titled "Treatment of attention-deficit/hyperactivity disorder - 3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof." This patent describes effective nicotinic receptor agonist compounds that have demonstrated pharmacological effects for symptoms associated with ADHD.

Career Highlights

Earle E Bain is associated with Abbott Laboratories Corporation, a leading global healthcare company. His work at Abbott has allowed him to focus on innovative treatments that improve the quality of life for individuals with ADHD.

Collaborations

Throughout his career, Earle has collaborated with esteemed colleagues such as Walid M Abi-Saab and Sandeep Dutta. These collaborations have fostered a productive environment for research and development in the field of ADHD treatment.

Conclusion

Earle E Bain's contributions to ADHD treatment through his patented innovations highlight his role as a significant figure in pharmacology. His work continues to influence the development of effective therapies for managing ADHD symptoms.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…